AMR Crisis Experts See Hopeful Signs For 2020
But Worries Rise US Politics May Stop Needed Progress
2020 could be a watershed year in tackling AMR, but success needs market reforms that ensure new antibiotics get to market and prevent innovators going bust, experts tell Scrip.
You may also be interested in...
Antibiotics specialist Antabio aims to get enough funding to advance its pipeline far enough to become a takeover target.
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
AstraZeneca has vowed to slash its carbon emissions to zero by 2025 and ensure its entire value chain is carbon negative by 2030. It will spend up to $1bn to do so.